Molecular Profile Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

Profile Name IDH1 wild-type
Gene Variant Detail

IDH1 wild-type (no effect)

Relevant Treatment Approaches

Filtering

  • Case insensitive filtering will display rows if any text in any cell matches the filter term
  • Use simple literal full or partial string matches
  • Separate multiple filter terms with a space. Any order may be used (i. e. a b c and c b a are equivalent )
  • Filtering will only apply to rows that are already loaded on the page. Filtering has no impact on query parameters.
  • Use quotes to match on a longer phrase with spaces (i.e. "mtor c1483f")

Sorting

  • Generally, the default sort order for tables is set to be first column ascending; however, specific tables may set a different default sort order.
  • Click on any column header arrows to sort by that column
  • Hold down the Shift key and click multiple columns to sort by more than one column. Be sure to set ascending or descending order for a given column before moving on to the next column.

Clinical Trial Phase Therapies Title Recruitment Status Covered Countries Other Countries
NCT03220646 Phase II Abemaciclib Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors Active, not recruiting USA 0
NCT03743662 Phase II Nivolumab Bevacizumab Nivolumab With Radiation Therapy and Bevacizumab for Recurrent MGMT Methylated Glioblastoma Active, not recruiting USA 0
NCT03696355 Phase I GDC-0084 Study of GDC-0084 in Pediatric Patients With Newly Diagnosed Diffuse Intrinsic Pontine Glioma or Diffuse Midline Gliomas Completed USA 0
NCT03018288 Phase II Pembrolizumab + Temozolomide Pembrolizumab + Temozolomide + Vitespen Radiation Therapy Plus Temozolomide and Pembrolizumab With and Without HSPPC-96 in Newly Diagnosed Glioblastoma (GBM) Terminated USA 0
NCT01891747 Phase I Bevacizumab + Temozolomide A Phase I Study of High-dose L-methylfolate in Combination With Temozolomide and Bevacizumab in Recurrent High Grade Glioma Completed USA 0
NCT05859334 Phase II Erdafitinib Testing the Anti-cancer Drug Erdafitinib for Brain Cancers That Have Returned or Progressed Following Treatment Recruiting USA 0
NCT04573192 Phase Ib/II Lomustine + Onfekafusp alfa Lomustine A Study to Evaluate Safety and Efficacy of L19TNF Plus Lomustine in Patients With Glioblastoma at First Progression (GLIOSTAR) Recruiting ITA | FRA | DEU | CHE 0
NCT04225039 Phase II INCAGN01876 + Retifanlimab Anti-GITR/Anti-PD1/Stereotactic Radiosurgery, in Recurrent Glioblastoma Active, not recruiting USA 0
NCT04910022 Phase Ib/II NMS-03305293 + Temozolomide Lomustine Ph I/II Study of NMS-03305293+TMZ in Adult Patients With Recurrent Glioblastoma Active, not recruiting USA | NLD | ITA | CHE 1
NCT03896568 Phase I DNX-2401 MSC-DNX-2401 in Treating Patients With Recurrent High-Grade Glioma Recruiting USA 0
NCT03452930 Phase I Tinostamustine Tinostamustine With or Without Radiation Therapy in Treating Patients With Newly Diagnosed MGMT-Unmethylated Glioblastoma Completed USA 0
NCT03631836 Phase I Andecaliximab + Bevacizumab Phase I Study of Monoclonal Antibondy (GS) 5745, an Matix Metalloproteinase 9 (MMP9) Mab Inhibitor, in Combination With Bevacizumab in Patients With Recurrent Glioblastoma (MARELLE01) Unknown status FRA 0